China genomics giant BGI targets A-share IPO

BGI, one of the world’s largest genome sequencing firms, plans to list in China to help fund growth and acquisitions but it is unclear if the IPO will see light in 2016.

BGI, one of the world’s largest genome sequencing companies, is targeting an A-share Chinese listing to help raise capital for development and acquisitions, some of them overseas.

However, it is unclear when the eye-catching initial public offering will see light.

The company, which previously abandoned plans to list in Hong Kong, aims to launch the IPO by the end of the year, Mao Mao, BGI's newly appointed chief science officer, told Chinese media last week.

But one person with knowledge of the matter told FinanceAsia that BGI is “very unlikely” to go public within the year, given the current...

¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222